Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alpha combined with toripalimab as second-line treatment for platinum-resistant recurrent/metastatic or unresectable locally advanced head and neck squamous cell carcinoma
ChiCTR2400085098Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- May 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab and interferon alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Planned start May 2024; status: not yet recruiting.
02
Drugs
toripalimabinterferon alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400085098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085098.